The Clinical and Economic Burden of Nonalcoholic Steatohepatitis

被引：0

作者：

Brian Lam

Kyle Kurzke

Zobair Younossi

机构：

[1] Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, 22042, VA

[2] Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA

来源：

Current Hepatology Reports | 2018年 / 17卷 / 4期

关键词：

Cost analysis; Economic burden; HEOR; NAFLD; NASH; Steatohepatitis;

D O I：

10.1007/s11901-018-0423-9

中图分类号：

学科分类号：

摘要：

Purpose of review: Nonalcoholic fatty liver disease (NAFLD) will be the dominant and most impactful liver disease for the next generation. As the obesity and diabetes epidemic continues and the general populations in most industrialized countries become older, NAFLD and its progressive subtype nonalcoholic steatohepatitis (NASH) will have a significant clinical and economic impact on society, both in the USA and globally. This manuscript provides a review of recently published articles that detail the impact of NAFLD and NASH. Recent findings: Overall, the literature shows that NAFLD is the most common liver disease globally, and that NASH is poised to become one of the dominant drivers of cirrhosis and hepatocellular carcinoma. Decompensated cirrhosis due to NASH will soon be the leading indication for liver transplantation. Costs increase significantly as patients progress to later stages of liver disease. Overall, the annual direct medical costs related to NAFLD are estimated to be near $100 billion in the USA and over €35 billion in Europe. The price tag almost triples if indirect costs are included. The global impact of NAFLD and NASH is projected to increase, with a 178% increase in liver-related deaths by 2030. Summary: The clinical and economic impact of NAFLD and NASH will be immense in the upcoming decades. This highlights the great need for better screening, surveillance, linkage to care, risk stratification, and treatment options. © Springer Science+Business Media, LLC, part of Springer Nature 2018.

引用

页码：345 / 349

页数：4

共 37 条

[1]

Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M., Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 1, pp. 73-84, (2016)

[2]

Younossi Z., Anstee Q.M., Marietti M., Hardy T., Henry L., Eslam M., George J., Bugianesi E., Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, 15, 1, pp. 11-20, (2018)

[3]

Fan J.-G., Zhu J., Li X.-J., Chen L., Li L., Dai F., Li F., Chen S.Y., Prevalence of and risk factors for fatty liver in a general population of Shanghai, China, J Hepatol, 43, 3, pp. 508-514, (2005)

[4]

Zhou Y.-J., Li Y.-Y., Nie Y.-Q., Ma J.-X., Lu L.-G., Shi S.-L., Chen M.H., Hu P.J., Prevalence of fatty liver disease and its risk factors in the population of South China, World J Gastroenterol, 13, 47, pp. 6419-6424, (2007)

[5]

Li H., Wang Y.-J., Tan K., Zeng L., Liu L., Liu F.-J., Zhou T.Y., Chen E.Q., Tang H., Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China, HBPD INT, 8, 4, pp. 377-382, (2009)

[6]

Younossi Z.M., Loomba R., Anstee Q.M., Rinella M.E., Bugianesi E., Marchesini G., Et al., Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis, Hepatology, 68, 1, pp. 349-360, (2018)

[7]

Hossain N., Afendy A., Stepanova M., Nader F., Srishord M., Rafiq N., Et al., Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 7, 11, pp. 1224-1229, (2009)

[8]

Cusi K., Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions, Diabetologia, 59, 6, pp. 1112-1120, (2016)

[9]

Estes C., Razavi H., Loomba R., Younossi Z., Sanyal A.J., Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, 67, 1, pp. 123-133, (2018)

[10]

Lazo M., Hernaez R., Eberhardt M.S., Bonekamp S., Kamel I., Guallar E., Koteish A., Brancati F.L., Clark J.M., Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994, Am J Epidemiol, 178, 1, pp. 38-45, (2013)

← 1 2 3 4 →